Physician profile
Daniel Marck
NPI 1750466082
$2,657.24
in general payments reported to CMS, 2019-2025
13 companies · $253 in 2025
The $253 reported for 2025 was more than what 92% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $446 · 2023: $501 · 2024: $1,149 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $902.25 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $360.64 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $325.68 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $265.97 | 2022-2024 | Entyvio |
| Qol Medical, LLC | $219.06 | 2021-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $212.61 | 2024-2025 | Omvoh |
| Abbvie INC. | $197.31 | 2021-2024 | |
| Redhill Biopharma INC. | $58.27 | 2022-2023 | Movantik, Talicia, Aemcolo |
| Nestle Healthcare Nutrition INC. | $40.50 | 2022-2023 | |
| Braintree Laboratories, INC. | $33.56 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.61 | 2023 | Ultomiris |
| Aimmune Therapeutics, INC. | $13.72 | 2024 | |
| Intercept Pharmaceuticals, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Marck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.